NeurologyLive®
@neurology_live
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments
ID: 1016356467073585152
http://neurologylive.com 09-07-2018 16:20:39
36,36K Tweet
9,9K Followers
742 Following
Grateful to have been part of the update and launch of the Oxford Health Policy Forum campaign MS Brain Health’s new report “Brain Health: Time Matters” which now includes #NMOSD & #MOGAD at #ECTRIMS 🧠 Mitzi Joi Williams, MD, FAAN European MS Platform MS Int'l Federation Gavin Giovannoni, aka Prof G
Fascinating talk by Sudarshini Ramanathan on B cells tolerance in #NMOSD #ECTRIMS2024. Sydney Health Brain & Mind Centre Kids Research
MS nursing: This slide is very important for nurses taking care of MS patients. UConn Health American Academy of Neurology National MS Society UConn Neurology Residency
Thanks to all the late-breaking presenters—and to the audience for asking so many excellent questions. There is a lot to digest from this session here at #ECTRIMS2024. Keep an eye out for our coverage of the presentations on NeurologyLive®!
A new analysis from the MAGNIFY-MS study suggested that treatment with cladribine tablets resulted in low overall disability accrual in patients with highly-active #MultipleSclerosis. EMD Serono #ECTIRMS2024 ECTRIMS Università Vita-Salute San Raffaele neurologylive.com/view/cladribin…
From #ECTRIMS2024 late-breaking session: The positive finding on the secondary end point of 6-month confirmed disability worsening in GEMINI 1 and 2 supports the data from the phase 3 HERCULES trial in secondary progressive multiple sclerosis. Read more: neurologylive.com/view/tolebruti…
Data from a phase 3 study suggested a 450-mg dose of ublituximab-xiiy can be administered in 1 hour as the initial infusion for patients with #MS who are B-cell depleted without additional safety concerns. TG Therapeutics ECTRIMS #ECTRIMS2024 Rocky Mountain MS neurologylive.com/view/enhance-d…
A study revealed nearly 1/5 of all lesions remyelinated over a 2-year period with cladribine, an FDA-approved disease-modifying therapy, among patients with highly active relapsing-remitting #MultipleSclerosis. EMD Serono ECTRIMS #ECTRIMS2024 PUCRS International neurologylive.com/view/remyelina…
🗣️🎙️We recently spoke with Peter Calabresi, of Johns Hopkins University, who discussed the new updates to the #MultipleSclerosis diagnostic criteria presented at #ECTRIMS2024, held September 18-20, in Copenhagen, Denmark. 🎥 🧠 Check out the interview on our site now! ECTRIMS
Take 5️⃣ minutes to stay up-to-date with our #FridayFive today! 👉 National MS Society Blog Post 👉 Guest Article w/ CareYaya 👉 #ECTRIMS2024 w/ Peter Calabresi 👉 NeuroVoices w/ Dr Antonio Scalfari 👉 Mind Moments w/ Edgewise Therapeutics 🖐 neurologylive.com/view/neurology…
📙 During #ECTRIMS2024, we share a new blog that features Nicole M. Boschi, PhD, of the National MS Society, who talked about the impact of the upcoming Medicare Part D and Medicare Advantage changes for the #MS community. Check it out on our site now! 🧡
Recently, we talked with Shamik Bhattacharyya, of Harvard Medical School and Brigham and Women's Hospital, who discussed a study presented at #ECTRIMS2024 that compared the effectiveness and safety profiles of FDA-approved #NMOSD therapies with other commonly used treatments. ECTRIMS